Table 4

Duration of myelotoxicity and bone marrow dosimetry

Cohort Groupa (GBq/m2)Gy/GBq→bone marrowcGy→bone marrowGranulocytopenia k/mm3 (days)Thrombocytopenia k/mm3 (days)
<1500<1000<500<75<50<25
1A (0.370)1.8129000000
1A (0.370)1.4121800600
1A (0.370)1.71253420714140
2A (0.555)1.81902720830217
2A (0.555)1.8223770700
2A (0.555)1.61991600700
3A (0.740)2.2289117014100
3A (0.740)2.027473010105
3A (0.740)1.22140001600
3A (0.740)2.4327232021111
3A (0.740)1.9295770730
1B (0.185)1.359000000
1B (0.185)1.459000000
1B (0.185)1.663000000
2B (0.370)1.8142000000
2B (0.370)1.171000000
2B (0.370)1.61281520000
  • a A cohorts, ≤10% of axial skeleton involved by prostate cancer on bone scan; B cohorts, >10% but ≤25% axial skeleton involved by prostate cancer on bone scan.